<?xml version="1.0" encoding="UTF-8"?>
<p id="Par31">At this time, there are 17 new RSV vaccines and biologicals in a pipeline of clinical trials while another 28 are in pre-clinical development [
 <xref ref-type="bibr" rid="CR68">68</xref>]. Numerous new molecules have already been characterized as capable of inhibiting RSV dissemination within the airways and are investigated as potential candidates for pre-clinical and clinical development [
 <xref ref-type="bibr" rid="CR66">66</xref>].
</p>
